Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-27T16:40:42.312Z Has data issue: false hasContentIssue false
  • English
  • Français

Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’)

Published online by Cambridge University Press:  02 January 2018

Philip K. Mcguire ,
Helen Cope  and
Thomas A. Fahy
Philip K. Mcguire*
Affiliation:
Institute of Psychiatry, London
Helen Cope
Affiliation:
Institute of Psychiatry, London
Thomas A. Fahy
Affiliation:
King's College Hospital, London
*
Dr McGuire, Institute of Psychiatry, London SE5 8AF
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’) has become one of the most widely used illicit substances in the UK. Little is known of the psychiatric morbidity which may be associated with its use. We have examined this association by collecting a series of psychiatric cases in which MDMA use was a prominent feature.

Method

Patients presenting between 1990 and 1992 with psychiatric symptoms which developed in the context of MDMA use (n = 13) were interviewed, and their psychiatric, medical and drug history, sociodemographic background and mental state were examined in detail. The psychopathology of cases with psychosis (n = 8) was assessed with the Present State Examination and compared with that of substance-naïve psychotic controls (n = 40).

Results

Eight patients presented with psychotic syndromes, two experienced visual illusions, hallucinations and palinopsia, one had panic attacks, one suffered from depression, and one described chronic depersonalisation and derealisation. The psychopathology of the patients with psychoses was very similar to that of controls.

Conclusions

Use of MDMA may be associated with a broader spectrum of psychiatric morbidity than heretofore suspected. Cases with psychosis may be clinically similar to psychotic patients with no history of substance use.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 165 , Issue 3 , September 1994 , pp. 391 - 395
Copyright
Copyright © Royal College of Psychiatrists, 1994 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baumgartner, W. A., Hill, V. A. & Bland, W. H. (1989) Hair analysis for drugs of abuse. Journal of Forensic Sciences, 34, 1433–1453.Google Scholar
Benazzi, F. & Mazzoli, M. (1991) Psychiatric illness associated with ‘ecstasy’. Lancet, 338, 1520.Google Scholar
Breakey, W. R., Goodell, H., Lorenz, P. C., et al (1974) Hallucinogenic drugs as precipitants of schizophrenia. Psychological Medicine, 4, 255–261.CrossRefGoogle ScholarPubMed
Creighton, F. J., Black, D. L. & Hyde, C. E. (1991) ‘Ecstasy’ psychosis and flashbacks. British Journal of Psychiatry, 159, 713–715.Google Scholar
Ellis, P. & Schimmel, P. (1989) Ecstasy abuse. New Zealand Medical Journal, 102, 358.Google Scholar
Hayner, G. N. & McKinney, H. (1986) The dark side of ecstasy. Journal of Psychoactive Drugs, 18, 341–347.Google Scholar
Jones, P. B., Bebbington, P., Forester, A., et al (1992) Premorbid social underachievement in schizophrenia. Results from the Camberwell Collaborative Psychosis Study. British Journal of Psychiatry, 162, 65–71.Google Scholar
Keshavan, M. S. & Lishman, W. A. (1986) Prolonged depersonalisation following cannabis abuse. British Journal of Addiction, 41, 140–142.Google Scholar
McGuire, P. & Fahy, T. (1991a) Chronic paranoid psychosis after misuse of MDMA (‘Ecstasy’). British Medical Journal, 302, 697.CrossRefGoogle Scholar
McGuire, P. & Fahy, T. (1991b) Flashbacks following MDMA. British Journal of Psychiatry, 160, 276.Google Scholar
McGuire, P., Jones, P., Harvey, I., et al (1994) Cannabis and acute psychosis. Schizophrenia Research (in press).Google Scholar
McKenna, D. J. & Petrouka, S. J. (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Journal of Neurochemistry, 54, 14–22.CrossRefGoogle ScholarPubMed
Price, L. P., Ricaurte, G. A., Krystal, J. H., et al (1989) Neuroendocrine and mood response to intravenous L-tryptophan in MDMA users. Archives of General Psychiatry, 46, 20–22.Google Scholar
Ricaurte, G. A., Martello, A. L., Katz, J. L., et al (1992) Lasting effects of 3,4 MDMA on central serotonergic neurons in non-human primates. Journal of Pharmacology and Experimental Therapeutics, 251, 616–622.Google Scholar
Schifano, F. (1991) Chronic atypical psychosis associated with MDMA (‘Ecstasy’) abuse. Lancet, 338, 1335.CrossRefGoogle ScholarPubMed
Vardy, M. M. & Kay, S. R. (1983) LSD psychosis or LSD-induced schizophrenia? Archives of General Psychiatry, 40, 877–883.Google Scholar
Whittaker-Azmitia, P. M. & Aronson, T. A. (1989) ‘Ecstasy’ (MDMA)-induced panic. American Journal of Psychiatry, 146, 119.Google Scholar
Wing, J. K., Cooper, J. E. & Sartorius, N. (1983) The Measurement and Classification of Psychiatric Symptoms. Cambridge University Press.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.